InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users

LITTLE ROCK – A University of Arkansas for Medical Sciences (UAMS) BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

By | 2015-08-26T09:02:59+00:00 January 29th, 2015|News Release, UAMS News|0 Comments